期刊文献+

系统性红斑狼疮相关肺动脉高压26例临床分析 被引量:1

Clinical analysis of 26 cases of pulmonary arterial hypertension in patients with systemic lupus erythematosus
暂未订购
导出
摘要 目的:探讨系统性红斑狼疮(SLE)相关肺动脉高压(PAH)的临床表现、诊治和预后。方法:回顾性分析26例SLE合并PAH住院患者的临床和随访资料。按PAH数据,将其分为轻中度组(40~60mmHg)和重度组(≥61mmHg)结果:患者主要临床表现是呼吸困难(88.5%)、雷诺现象(57.7%),心功能分级Ⅰ、Ⅱ、Ⅲ、Ⅳ级分别占10.8%、37.8%、27%、24.3%。治疗后肺动脉收缩压(PASP)由(67.0±25.9)mmHg降至(52.6±20.0)mmHg(P<0.05)。平均随访6.7±5.4个月,死亡率15.4%。重度组雷诺现象、SLE疾病活动指数(SLEDAI)评分及肺间质病变发生率均显著高于轻中度组(均P<0.05)。结论:SLE相关PAH的主要表现是呼吸困难、雷诺现象。重度PAH患者死亡率高,定期对SLE患者进行超声心动图检查对筛查PAH非常必要。 Objective:To investigate the clinical features and prognosis of pulmonary arterial hypertension(PAH)secondary to systemic lupus erythematosus(SLE).Methods:Twenty-six patients diagnosed as having SLE associated PAH were retrospectively analyzed.The patients were grouped to severe PAH group(≥61mmHg)and mild and moderate group(40~60mmHg),respectively.Results:The most common clinical manifestations of SLE associated PAH were dyspnea on exertion(88.5%)and Raynaud′s phenomenon(57.7%).The mean pulmonary artery systolic pressure(PASP)in SLE patients received treatment for arterial pulmonary vasodilators and immunosuppressive agents,the condition of elevated PASP had decrease from(67.0±25.9)mmHg to(52.6±20.0)mmHg.Among them,15.4% patients died during an average of 6.7±5.4 months follow-up.More Raynaud′s phenomenon,higher SLEDAI and rates of interstitial lung disease were observed in severe PAH group compared to mild and moderate group(all P0.05).Conclusion:The most common manifestations of SLE associated PAH are dyspnea on exertion and Raynaud′s phenomenon.SLE associated PAH could be very severe,and therefore reduce the survival rates of the patients.Doppler echocardiography are necessary to detect PAH early.
出处 《中日友好医院学报》 2012年第2期83-85,共3页 Journal of China-Japan Friendship Hospital
关键词 肺动脉高压 红斑狼疮 系统性 超声心动描记术 pulmonary hypertension lupus erythematosus systemic echocardiography
  • 相关文献

参考文献9

  • 1Can MM,Kaymaz C,Tanboga IH,et al.Increased right ven-tricular glucose metabolism in patients with pulmonary arte-rial hypertension[J].Clin Nucl Med,2011,36:743-748.
  • 2Rich S.Primary pulmonary hypertension.The World Sympo-sium-Primary pulmonary hypertension,1998.
  • 3Thenappan T,Shah SJ,Rich S,et al.A USA-based registryfor pulmonary arterial hypertension:1982-2006[J].Eur RespirJ,2007,30:1103-1110.
  • 4Ruiz-Arquelles A,Anqles-Cano E,Perez-Romano B,et al.Serum antibodies to distinct epitopes of the tissue-typeplasminogen activator(t-PA)in patients with systemic lupuserythematosus[J].Am J Hematol,1995,49:109-114.
  • 5Shen JY,Chen SL,Wu YX,et al.Pulmonary hypertension insystemic lupus erythematosus[J].Rheumatol Int,1999,18:147-151.
  • 6Nishimaki T,Aotsuka S,Kondo H,et al.Immunological analy-sis of pulmonary hypertension in connective tissue diseases[J].J Rheumatol,1999,26:2357-2362.
  • 7Chritman BW,Mcpherson CD,Newman JH,et al.An imbal-ance between the excretion of thromboxane and prostacyclinmetabolites in pulmonary hypertension[J].N Engl J Med,1992,327:70-75.
  • 8Jing ZC,Xu XQ,Har ZY,et al.Registry and survival studyin Chinese paitients with idiopathic and familial pulmonaryarterial hypertension[J].Chest,2007,132:373-379.
  • 9Simonson JS,Schiller NB,Petri M,et al.Pulmonary hyperten-sion in systemic lupus erythematosus[J].J Rheumatol,1989,16:918-925.

同被引文献41

  • 1荆志成.2010年中国肺高血压诊治指南[J].中国医学前沿杂志(电子版),2011,3(2):62-81. 被引量:121
  • 2黄子扬,沈学东.三尖瓣狭窄的彩色多普勒超声心动图评价[J].中国超声医学杂志,1995,11(9):706-707. 被引量:2
  • 3McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension : a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association:developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation, 2009,119 (16) : 2250-2294.
  • 4Simonnean G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension.J Am Coll Cardiol, 2009,54 ( 1 Suppl) :$43-$54.
  • 5Hassoun PM.Pulmonary arterial hypertension complicating connective tissue diseases.Semin Respir Crit Care Med, 2009,30 (4) :429-439.
  • 6Prabu A, Patel K, Yee CS, et al. Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. Rhemnatology (Oxford) ,2009,48(12) : 1506-1511.
  • 7Winslow TM, Ossipov MA, Fazio GP, et al. Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J, 1995,129 (3) : 510-515.
  • 8Haas C. Pulmonary hypertension associated with systemic lupus erythematosus.Bull Acad Natl Med, 2004,188 (6) : 985-997.
  • 9Arnand L, Agard C, Haroche J, et al. Pulmonary arterial hypertension in systemi,: lupus erythematosus. Rev Med Interne, 2011,32 ( 11 ) : 689-697.
  • 10Farber HW, Foreman AJ, Miller DP, et al. REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. Congest Heart Fail, 2011,17(2) :56-64.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部